Global Joint Pain Injections Market Size By Type (Corticosteroid Injections, Hyaluronic Acid Injections), By Application (Hospital Pharmacies, Retail Pharmacies), By Region, And Segment Forecasts, 202...

The Global Joint Pain Injections Market was valued at USD 4.3 billion in 2023 and is projected to reach USD 7.6 billion by 2031, growing at a CAGR of 7.2% during the forecast period from 2023 to 2031. The market growth is primarily driven by the increasing prevalence of osteoarthritis and rheumatoid arthritis, rising geriatric population, and growing preference for minimally invasive treatment options. Joint pain injections, including corticosteroids, hyaluronic acid, and platelet-rich plasma (PRP), offer localized relief, improved mobility, and delay in surgical intervention, making them an increasingly favored choice among both patients and healthcare providers.

Drivers:

1. Rising Prevalence of Joint Disorders:

The increasing incidence of arthritis-related conditions globally, particularly among aging populations, is significantly driving demand for joint pain management therapies. According to WHO, osteoarthritis affects 528 million people worldwide, fueling market demand for intra-articular injections.

2. Increasing Geriatric Population:

With a growing elderly population, the susceptibility to joint pain, stiffness, and cartilage degeneration rises. As older individuals seek effective and quick pain relief without major surgery, the demand for joint pain injections continues to grow.

3. Advancements in Injection Therapies:

Innovations in biologic injections, such as PRP and stem cell-based therapies, have expanded treatment options and boosted adoption among younger, more active patients as well, aiming for quicker recovery and regenerative benefits.

Restraints:

1. High Cost of Advanced Therapies:

While conventional corticosteroid injections are affordable, newer biologic therapies like PRP and stem cells are expensive and often not covered by insurance, limiting accessibility in lower-income populations.

2. Risk of Adverse Effects and Repetitive Use Limitations:

Repeated corticosteroid injections can lead to cartilage damage and joint deterioration. Awareness of potential side effects and physician caution regarding frequency of administration may hinder repeated sales.

Opportunity:

1. Increasing Demand for Biologic and Regenerative Therapies:

With the rising popularity of natural healing mechanisms and personalized medicine, biologic injections such as PRP and stem cell therapies present significant growth opportunities, particularly in sports medicine and early-stage osteoarthritis treatment.

2. Expanding Healthcare Infrastructure in Emerging Markets:

Countries in Asia-Pacific and Latin America are investing in healthcare modernization, which includes access to advanced orthobiologic therapies. This expansion is expected to provide lucrative opportunities for market penetration.

Market by System Type Insights:

Corticosteroid Injections dominated the market in 2023 due to their low cost and wide acceptance in clinical settings for short-term pain relief. However, Hyaluronic Acid Injections are expected to witness the fastest growth over the forecast period, attributed to their role in long-term joint lubrication and lower risk of side effects. Platelet-Rich Plasma (PRP) Injections are also gaining momentum, driven by demand for natural and regenerative treatment solutions.

Market by End-use Insights:

Hospitals and Orthopedic Clinics held the largest market share in 2023, accounting for over 55% of the global revenue. Their access to skilled professionals and advanced imaging techniques enables effective joint injection administration. Ambulatory Surgical Centers (ASCs) are expected to grow rapidly due to the increasing preference for outpatient procedures with faster turnaround and lower costs.

Market by Regional Insights:

North America dominated the global joint pain injections market in 2023, supported by high awareness, advanced healthcare systems, and greater access to biologic therapies. Asia-Pacific is forecast to grow at the fastest CAGR during 2023–2031, driven by a rapidly aging population, growing orthopedic care demand, and increasing investment in regenerative medicine.

Competitive Scenario:

Major players in the Global Joint Pain Injections Market include Sanofi S.A., Zimmer Biomet, Seikagaku Corporation, Bioventus LLC, Anika Therapeutics Inc., Johnson & Johnson, Ferring Pharmaceuticals, and Teva Pharmaceutical Industries Ltd. These companies are focused on expanding their biologic injection portfolios, obtaining regulatory approvals, and entering strategic partnerships to strengthen market presence.

Scope of Work – Global Joint Pain Injections Market

Key Market Developments:

2023: Anika Therapeutics launched its next-generation hyaluronic acid-based injection tailored for long-term knee osteoarthritis relief.

2024: Bioventus received expanded regulatory approval for its PRP system across multiple countries in Asia-Pacific.

2025: Zimmer Biomet partnered with a regenerative medicine startup to co-develop novel stem cell injection solutions for early-stage joint degeneration.

FAQs:

1) What is the current market size of the Global Joint Pain Injections Market?

The market was valued at USD 4.3 billion in 2023.

2) What is the major growth driver of the Global Joint Pain Injections Market?

The increasing prevalence of arthritis and a growing preference for minimally invasive treatments are the key drivers.

3) Which is the largest region during the forecast period in the Global Joint Pain Injections Market?

North America holds the largest market share.

4) Which segment accounted for the largest market share in Global Joint Pain Injections Market?

Corticosteroid Injections accounted for the largest market share in 2023.

5) Who are the key market players in the Global Joint Pain Injections Market?

Key players include Sanofi, Zimmer Biomet, Seikagaku Corporation, Bioventus, and Anika Therapeutics.